42 results about "Transcription regulator" patented technology

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

This invention provides a nucleic acid construct comprising; (i) a first nucleotide sequence for expression, (ii) a first promoter operably linked to the first nucleotide sequence, said first promoter being inducible, (iii) a first insulating sequence located upstream of the first nucleotide sequence and first promoter, (iv) a second insulating sequence located downstream of the first nucleotide sequence and first promoter, (v) a second nucleotide sequence encoding a transcription regulator protein that induces expression from the first promoter; and (vi) a second promoter operably linked to the second nucleotide sequence. The second nucleotide sequence and second promoter may be located either (a) upstream of the first insulating sequence or (b) downstream of the second insulating sequence. Also provided are vectors and mammalian cells comprising the construct, methods of inducibly expressing a nucleotide sequence in the construct, and methods of producing a mammalian cell by inducing expression from the construct.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

To provide a transcriptional regulator protein degradation-promoting composition that is capable of directly facilitating the induction of transcription regulator protein degradation and also capable of enhancing the degradation-inducing effect through the combined administration of multiple components, wherein the transcriptional regulator protein degradation-promoting composition serves as a highly effective cancer therapeutic agent, as well as to provide a therapeutic agent comprising the same.SOLUTION: The present invention provides a transcriptional regulator protein degradation-promoting composition that facilitates the degradation of the transcription regulator protein, comprising a PARG inhibitor, a PERK inhibitor, an HSP90 inhibitor, or a histone acetylation enzyme inhibitor, as well as a therapeutic agent comprising the same.SELECTED DRAWING: None

The invention relates to the technical field of biology, in particular to application of YAP related protein in intestinal ischemia-reperfusion lung injury. The application comprises the application of the overexpressed YAP related protein 1 in treating or inhibiting the intestinal ischemia-reperfusion lung injury; based on the regulation and control effect of a transcriptional regulatory factor of the YAP-associated protein 1 in a Hippo-YAP signal channel, accumulation of overexpressed YAP-associated protein 1 in a cell nucleus is used, so that a large amount of YAP-associated protein 1 is overexpressed in the cell nucleus, expression of downstream Nrf2 genes in the cell nucleus and transfer of the YAP-associated protein 1 in the cell nucleus can be regulated and controlled, and the YAP-associated protein 1 can be expressed in the cell nucleus. According to the present invention, the overexpressed YAP-associated protein 1 can be used to inhibit ferroptosis of intestinal ischemia-reperfusion lung injury tissues, and the overexpressed YAP-associated protein 1 can be used to improve lung injury, such that the overexpressed YAP-associated protein 1 can be used to protect lung epithelium injury caused by intestinal ischemia-reperfusion.

Disclosed are systems and methods for detecting extracellular ligands and / or inducing expression of an exogenous or endogenous gene. The disclosed systems and methods typically include and / or utilize (i) first and second exogenous extracellular sensors, and third and fourth exogenous extracellular sensors; and (ii) an expression vector comprising a target gene operably linked to a hybrid promoter sequence. The hybrid promoter sequence of the expression vector includes a minimal promoter for inducing transcription and the hybrid promoter sequence further includes interspaced transcription regulator binding sites upstream of the minimal promoter that bind two or more transcription regulators of the extracellular sensors that are released from the extracellular sensors when the extracellular sensor bind an extracellular ligand.

The invention relates to Escherichia coli with high yield of 2 '-fucosyllactose as well as a construction method and application of the Escherichia coli, and belongs to the technical field of genetic engineering. Alpha-1, 2-fucosyltransferase from neisseria is heterologously expressed in starting escherichia coli, a GDP-L-fucose synthesis route key enzyme coding gene cluster, a transcriptional regulation factor protein coding gene, a beta-galactoside permease coding gene and a sugar efflux transporter A coding gene are overexpressed, and a GDP-L-fucose synthesis route key enzyme coding gene cluster, a transcriptional regulation factor protein coding gene, a beta-galactoside permease coding gene and a glycosyl efflux transporter A coding gene are expressed. A beta-galactosidase coding gene, a UDP-glucose lipid carrier transferase coding gene, a GDP-mannosyl hydrolase coding gene and a galactoside O-acetyltransferase coding gene are knocked out, a recombinant escherichia coli strain with both yield and production efficiency is constructed, and in a fermentation system with glycerol as a carbon source, the recombinant escherichia coli strain with high yield and high production efficiency is obtained. The yield of the 2 '-fucosyllactose reaches 134.71 g / L, the production efficiency reaches 3.21 g / L.h, the industrial application potential is shown, and efficient production of the 2'-fucosyllactose is achieved.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The invention discloses application of a composition containing lycium barbarum polysaccharide. The lycium barbarum polysaccharide is used for achieving the effects of resisting aging and removing lipofuscin, particularly, the specific lycium barbarum polysaccharide LBP1C can more remarkably reduce the level of transcription factors GATA4, activate key transcription regulatory factors of autophagy, reduce aging-related secretion phenotypes and inhibit accumulation of lipofuscin, and the lycium barbarum polysaccharide LBP1C has the effects of delaying aging, whitening skin and promoting healthy aging.

The invention discloses the creation and application of an aromatic amide biosensor, and belongs to the field of bioengineering technology. The biosensor in the present invention is based on the amino acid motif of the transcriptional regulator AmiC-AmiR derived from Pseudomonas aeruginosa, and the RBS of AmiC and AmiR are optimized respectively, and the tyrosine at position 83 of AmiC is mutated to isoleucine, and the threonine at position 233 is mutated to cysteine. Compared with the wild-type transcriptional regulator AmiC-AmiR, the biosensor provided by the present invention has a good linear relationship in its responsiveness to aromatic amides, and the response range is between 0 and 10 mM after the optimization of RBS. The biosensor that can respond to aromatic amides provided by the present invention can be used for the detection of aromatic amides, screening strains that metabolize aromatic amides, or laying the foundation for subsequent research on aromatic amide production metabolic pathways, and has a wide range of application scenarios.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

To provide genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and to provide methods of generating the genetic modified cells.SOLUTION: The universal donor cells comprise at least one genetic modification within or near at least one gene encoding a survival factor, the genetic modification comprising the insertion of a polypeptide encoding a tolerogenic factor. The universal donor cell may further comprise at least one genetic modification within or near a gene encoding one or more MHC-I or MHC-II human leukocyte antigens or components or transcriptional regulators of the MHC-I or MHC-II complexes, the genetic modification comprising the insertion of a polypeptide encoding a second tolerogenic factor.SELECTED DRAWING: Figure 1

Senescent cells are implicated in aspects of age-related decline in health and may contribute to certain diseases. Embodiments include formulations and methods for promoting longevity and treating a senescence associated disease or disorder. Applicants present three distinct classes and multiple associated therapeutic molecules that can function alone or in combination with the other molecules. The classes include transcription regulators, lipid intermediates and microRNAs. Additional embodiments include methods of promoting longevity by administering GRAS substances.

The present invention relates to a gene variant of the transcriptional regulator LysG and a method for producing L-citrulline or L-arginine using same. The gene variant of the transcriptional regulator LysG according to the present invention has protein activity that is altered due to the mutation of one or more bases in the base sequence of a gene encoding the transcriptional regulator LysG, and thus, it is possible to effectively produce L-citrulline or L-arginine from a recombinant microorganism comprising the variant.

The invention relates to the technical field of microorganisms, and particularly discloses a recombinant microorganism for producing adenosine as well as a construction method and application of the recombinant microorganism. According to the method for constructing the recombinant microorganism, compared with an original strain, the recombinant microorganism has the transcriptional regulatory factor BkdR with enhanced activity, and the original strain can be fermented to produce adenosine. The invention further provides a BkdR protein mutant with improved transcriptional level. When the recombinant strain is applied to adenosine fermentation production, higher yield can be obtained, and the fermentation production efficiency is improved.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

The present application relates to a novel manganese dependent transcriptional regulator variant polypeptide; a polynucleotide encoding the variant polypeptide; a microorganism comprising the variant polypeptide, a polynucleotide encoding the variant polypeptide, or a vector carrying the polynucleotide; a method for producing L-glutamic acid, said method comprising the step of culturing said microorganism in a culture medium; and the use of said microorganism for the production of L-glutamic acid.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and / or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and / or a different survival factor.

The present invention relates to transcriptional regulator polypeptides, polynucleotides encoding the transcriptional regulator polypeptides, and to nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing a polypeptide of interest in host cells overexpressing the transcriptional regulators, to methods of increasing the oxygen uptake rate and / or decreasing viscosity of the culture broth in a fungal host cell cultivation process, to methods of producing a transcriptional regulator polypeptide, to the use of a transcriptional regulator polypeptide, and to the production of fungal biomass.

The present application relates to a novel manganese-dependent transcriptional regulator mutant polypeptide; a polynucleotide encoding the mutant polypeptide; a microorganism comprising the mutant polypeptide, a polynucleotide encoding the mutant polypeptide, or a vector comprising the polynucleotide; a method for producing L-glutamic acid, the method comprising culturing the microorganism in a medium; and use of the microorganism for producing L-glutamic acid.

The disclosure provides inducible constructs comprising transcription initiators and / or transcription regulators. These constructs may be used to drive expression of genes, in response to particular cell states (such as in the context of antigen stimulation). In some embodiments, the constructs are incorporated as a part of regulatory circuits useful to control expression and regulation of cells expressing engineered receptors.

The invention discloses an Lrp mutant and application thereof. The invention relates to an Lrp mutant and application thereof in the technical field of biology. The leucine-responsive transcriptional regulatory factor mutant provided by the invention is any one of the following: A1) a protein obtained by mutating the 107th histidine of a protein with an amino acid sequence of SEQ ID No: 1 into tyrosine; a2) a protein which is obtained by substitution and / or deletion and / or addition of amino acid residues on the protein of A1), has 75% or more of identity with the protein of A1) and has the same function as the protein of A1); and A3) a fusion protein obtained by connecting a protein tag to the N terminal or / and the C terminal of A1) or A2). The yield of the engineering strain L-valine is increased through site-specific mutagenesis, and the engineering strain has industrial application value.

The invention provides a combined module for enhancing symbiotic nitrogen fixation capacity of rhizobium and application, and belongs to the technical field of synthetic biology. The combined module for enhancing the symbiotic nitrogen fixation capacity of the rhizobium comprises an inducible promoter element Pi and a transcriptional regulatory factor coding gene tetR, wherein the inducible promoter element Pi and the transcriptional regulatory factor coding gene tetR are sequentially connected; the inducible promoter element Pi specifically responds to a symbiotic nitrogen fixation signal; according to the invention, the combined module is inserted into an initial vector to construct a recombinant expression vector, and the recombinant expression vector is transferred into different soybean rhizobium chassis through a triparental conjugation method to obtain two nitrogen fixation recombinant engineering strains; the recombinant engineering strain can recover the influence of glyphosate stress on the symbiotic nitrogen fixation capability of the rhizobium.

The present invention takes a novel transcriptional regulatory factor LysG mutant and a promoter regulated by it as research objects, and particularly relates to the advantages and applications of the mutant in regulating gene expression and high-throughput screening in metabolic engineering, and belongs to the field of metabolic engineering. The present invention obtains LysG by performing point mutation on LysG. E15D , A54D , I164V The mutant, under the regulation of histidine, increased the expression intensity of downstream genes by 7.5 times compared with the wild type, that is, the concentration of histidine can be used to regulate downstream genes with higher intensity, so it can be better used for metabolic engineering regulation and high-throughput screening of histidine-producing strains.

The invention belongs to the field of synthetic biology, and particularly relates to a dynamic regulation and control system based on quorum sensing and application thereof. The gene comprises a constitutive promoter, a signal molecule AHLs synthetase coding gene esaI, a segment of RBS sequence, a transcriptional regulatory factor synthetase coding gene esaRI70V, a quorum sensing target promoter PesaS and a threonine synthesis key gene thrB regulated by the quorum sensing target promoter PesaS. Accurate dynamic regulation and control of a threonine synthesis route are realized by adjusting the strength of the constitutive promoter in the system, addition of necessary amino acid threonine in the fermentation process of escherichia coli engineering bacteria is eliminated, an inducer does not need to be added, the regulation and control complexity and the fermentation cost in the fermentation process are effectively reduced, and the method is suitable for large-scale industrial production. The method has good production and application values.

The present disclosure relates to transcription regulator molecule compounds, compositions, and methods for the treatment of DM1 and FECD.

The present disclosure generally relates to multi-chain chimeric polypeptides or receptors having different polypeptide chains that associate post-translational to enable simultaneous activation of a signaling domain and release of a transcriptional regulatory factor following binding of a ligand. The disclosure also provides nucleic acid constructs, recombinant cells, vectors, pharmaceutical compositions and methods of treatment comprising the multi-chain chimeric polypeptides of the disclosure. The present disclosure also provides methods for simultaneous induction of T cell signaling and gene modulation in T cells.

The present disclosure generally relates to multi-chain chimeric polypeptides or receptors having distinct polypeptide chains that associate post-translationally to enable the simultaneous activation of the signaling domain and the release of a transcriptional regulator upon binding of a ligand. The disclosure also provides nucleic acid constructs, recombinant cells, vectors, pharmaceutical compositions, and methods of treatment including the multi-chain chimeric polypeptides of the disclosure. The disclosure further provides methods for simultaneously inducing T cell signaling and gene regulation in a T cell.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.